BACKGROUND: In patients with breast cancer (BC) a high prevalence of benign thyroid diseases (BTD) has been described, Hashimoto's thyroiditis accounting to a large extent for this association. The aim of this study was to evaluate the prevalence of BC in a large group of patients with BTD. PATIENTS: Clinical records of 622 consecutive patients with BTD were examined. BC prevalence in BTD patients was compared with BC frequency in general population living in the same country. RESULTS: BC prevalence in patients with BTD (38/622; 6.11%) was significantly higher (p=0.0002) compared to BC frequency in general population (2.07%). When patients were divided according to the age of menopause, in females older than 49 yr BC frequency in BTD was significantly higher than in age-matched population (7.6 vs 3.3%; p=0.006), while in females aged 30-49 yr BC frequency in BTD was higher, but not statistically significantly, than in agematched population (3.7 vs 0.5%; p=0.06). No significant difference in BC prevalence was found when patients were grouped according to the diagnosis of thyroid disorders: Graves' disease, Hashimoto's thyroiditis, nodular goiter associated or not associated with serum thyroid autoantibodies (TAb). No significant difference in BC frequency was observed between TAb+ (26/377; 6.9%) and TAb- (12/245; 4.9%) patients. The distribution of known risk factors for breast malignancies was similar in patients with or without BC. CONCLUSION: In patients with BTD the prevalence of BC is significantly higher than the expected, showing the usefulness of screening for breast malignancy of patients with BTD.
BACKGROUND: In patients with breast cancer (BC) a high prevalence of benign thyroid diseases (BTD) has been described, Hashimoto's thyroiditis accounting to a large extent for this association. The aim of this study was to evaluate the prevalence of BC in a large group of patients with BTD. PATIENTS: Clinical records of 622 consecutive patients with BTD were examined. BC prevalence in BTDpatients was compared with BC frequency in general population living in the same country. RESULTS: BC prevalence in patients with BTD (38/622; 6.11%) was significantly higher (p=0.0002) compared to BC frequency in general population (2.07%). When patients were divided according to the age of menopause, in females older than 49 yr BC frequency in BTD was significantly higher than in age-matched population (7.6 vs 3.3%; p=0.006), while in females aged 30-49 yr BC frequency in BTD was higher, but not statistically significantly, than in agematched population (3.7 vs 0.5%; p=0.06). No significant difference in BC prevalence was found when patients were grouped according to the diagnosis of thyroid disorders: Graves' disease, Hashimoto's thyroiditis, nodular goiter associated or not associated with serum thyroid autoantibodies (TAb). No significant difference in BC frequency was observed between TAb+ (26/377; 6.9%) and TAb- (12/245; 4.9%) patients. The distribution of known risk factors for breast malignancies was similar in patients with or without BC. CONCLUSION: In patients with BTD the prevalence of BC is significantly higher than the expected, showing the usefulness of screening for breast malignancy of patients with BTD.
Authors: H A Weiss; L A Brinton; N A Potischman; D Brogan; R J Coates; M D Gammon; K E Malone; J B Schoenberg Journal: Int J Epidemiol Date: 1999-10 Impact factor: 7.196
Authors: F Aghini-Lombardi; L Antonangeli; E Martino; P Vitti; D Maccherini; F Leoli; T Rago; L Grasso; R Valeriano; A Balestrieri; A Pinchera Journal: J Clin Endocrinol Metab Date: 1999-02 Impact factor: 5.958
Authors: Shilpi Rajoria; Robert Suriano; Arulkumaran Shanmugam; Yushan Lisa Wilson; Stimson P Schantz; Jan Geliebter; Raj K Tiwari Journal: Thyroid Date: 2010-01 Impact factor: 6.568
Authors: Orhan Turken; Yavuz NarIn; Sezai DemIrbas; M Emin Onde; Ozkan Sayan; E Gokhan KandemIr; Mustafa YaylacI; Ahmet Ozturk Journal: Breast Cancer Res Date: 2003-06-05 Impact factor: 6.466
Authors: C Chiappa; F Rovera; S Rausei; S Del Ferraro; A Fachinetti; M Lavazza; V Marchionini; V Arlant; M L Tanda; E Piantanida; H Y Kim; A Anuwong; G Dionigi Journal: J Endocrinol Invest Date: 2016-09-13 Impact factor: 4.256
Authors: A Losada-García; S A Cortés-Ramírez; M Cruz-Burgos; M Morales-Pacheco; Carlos D Cruz-Hernández; Vanessa Gonzalez-Covarrubias; Carlos Perez-Plascencia; M A Cerbón; M Rodríguez-Dorantes Journal: Front Genet Date: 2022-01-17 Impact factor: 4.599